Immune response against angiosarcoma following lower fluence rate clinical photodynamic therapy.
Tumor response to photodynamic therapy (PDT) is dependent on treatment parameters used. In particular, the light fluence rate may be an important determinant of the treatment outcome. In this clinical case report, we describe the response of angiosarcoma to PDT carried out using different fluence rates and drug and light doses. A patient with recurrent multifocal angiosarcoma of the head and neck was recruited for PDT. A new generation chlorin-based photosensitizer, Fotolon, was administered at a dose of 2.0 to 5.7 mg/kg. The lesions were irradiated with 665 nm laser light for a light dose of 65 to 200 J/cm2 delivered at a fluence rate of 80 or 150 mW/cm2. High dose PDT carried out at a high fluence rate resulted in local control of the disease for up to a year; however, the disease recurred and PDT had to be repeated. PDT of new lesions carried out at a lower fluence rate resulted in tumor eradication. More significantly, it also resulted in spontaneous remission of neighboring and distant untreated lesions. Repeat PDT carried out on a recurrent lesion at a lower fluence rate resulted in eradication of both treated and untreated lesions despite the lower total light dose delivered. Immunohistochemical examination of biopsy samples implies that PDT could have activated a cell-mediated immune response against untreated lesions. Subsequent histopathological examination of the lesion sites showed negative for disease. Our clinical observations show that lower fluence rate PDT results in better outcome and also indicate that the fluence rate, rather than the total light dose, is a more crucial determinant of the treatment outcome. Specifically, lower fluence rate PDT appears to activate the body's immune response against untreated lesions.
Division of Medical Sciences, National Cancer Centre, Singapore.
Patricia S P
PS
Thong
Malini
M
Olivo
Kiang-Wei
KW
Kho
Ramaswamy
R
Bhuvaneswari
William W L
WW
Chin
Kong-Wee
KW
Ong
Khee-Chee
KC
Soo
D002735:Chlorophyllides; D004305:Dose-Response Relationship, Drug; D004307:Dose-Response Relationship, Radiation; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D006394:Hemangiosarcoma / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects / Q000528:radiation effects; D007834:Lasers; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000276:immunology; D010778:Photochemotherapy / Q000379:methods*; D017319:Photosensitizing Agents / Q000008:administration & dosage / Q000627:therapeutic use; D011166:Porphyrins; D011205:Povidone; D011524:Protoporphyrins / Q000008:administration & dosage / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology
D002735:Chlorophyllides; D017319:Photosensitizing Agents; D011166:Porphyrins; D011524:Protoporphyrins; C062985:phytochlorin; D011205:Povidone